Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 17/08/2015 AG_Papatheodorou.jpg

    CDT – a bacterial toxin that mediates its own delivery into cells

    Clostridium difficile is totally harmless in healthy people. However, in combination with antibiotics it can cause severe diarrhoea and intestinal inflammation in elderly and debilitated people. But how does the spore-forming, rod-shaped bacterium deploy its power? And how does it enter the cell? Dr. Panagiotis Papatheodorou and his colleagues from the Institute of Experimental and Clinical Pharmacology and Toxicology (Director: Prof. Dr. Klaus…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/cdt-a-bacterial-toxin-that-mediates-its-own-delivery-into-cells
  • Press release - 03/04/2018 Simon Raffel, Lars Velten and Simon Haas.

    Double success for Heidelberg stem cell researchers

    Two awards at once, both carrying high monetary prizes, go to young researchers from the Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM) at the German Cancer Research Center (DKFZ): Simon Raffel will receive the 2018 Walter Schulz Prize. Simon Haas will share the 2018 Otto Schmeil Prize with his colleague Lars Velten from EMBL.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/double-success-for-heidelberg-stem-cell-researchers
  • Dossier - 22/08/2011 Volcanic crater in the Yellowstone National Park: The lake is surrounded by an orange ring consisting of algae and bacteria which have become adapted to the extremely high temperatures.<br />

    Stress and molecular defence mechanisms

    Organisms can experience stress from exposure to bacteria and pathogenic fungi; in fact, stress can arise from exposure to any type of environmental influence. As they have evolved, biological cells have developed numerous molecular mechanisms that enable them to survive even in inhospitable conditions. What kind of effects do abiotic stress factors have on plants and human beings? How do cells protect themselves? Are researchers able to increase…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/stress-and-molecular-defence-mechanisms
  • Dossier - 23/07/2012 17728_de.jpg

    Extremophilic bacteria

    What causes stress for some, actually speeds others like extremophilic bacteria up. They love it hot, sour or salty, toxic substances like heavy metals also do them good and even give them energy. As molecular and systems biology techniques get better and better, industry is also becoming increasingly interested in these exotic organisms. What potential does knowing the biochemistry of extremophilic bacteria have for the pharmaceutical, cosmetics…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/extremophilic-bacteria
  • Article - 20/01/2020 Bild_1.jpg

    Brain tumour patients could benefit from heavy ion therapy

    Glioblastoma is a malignant brain tumour. It does not respond anywhere near as well to conventional forms of therapy than other tumours because it contains particularly resistant cancer cells. Scientists at the Heidelberg Ion Beam Therapy Center (HIT) at Heidelberg University Hospital and the German Cancer Research Center have shown that heavy ion therapy is effective against these cells.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/Brain-tumour-patients-could-benefit-from-heavy-ion-therapy
  • Article - 18/02/2009 Portrait of Prof. Andreas Trumpp

    Dormant stem cells can be awakened with interferon alpha

    With a number of new papers published in renowned scientific journals Prof. Dr. Andreas Trumpp has been able to further cement his outstanding reputation as one of the world leaders in stem cell research. Trumpp who has been professor and head of the Department of Cell Biology at the German Cancer Research Centre DKFZ since summer 2008 also became head of the newly founded Heidelberg Institute for Stem Cell Technology and Experimental Medicine…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/dormant-stem-cells-can-be-awakened-with-interferon-alpha
  • Company profile - 27/06/2016 Schematic showing a host cell that is infected by an influenza virus that uses the MEK signalling pathway in the host cells to propagate (left). Several new viruses (red) have been released by the host cell. The schematic on the right-hand side shows the blockage of the signalling pathway. Crossed-out grey virus cells below the host cell indicate that the viruses are no longer able to replicate.

    Atriva Therapeutics GmbH: new ways to treat influenza

    Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/atriva-therapeutics-gmbh-new-ways-to-treat-influenza
  • Press release - 14/01/2008

    Prostate cancer: Improving the success of treatment

    Prostate cancer is the most frequent malignant tumour in men. Researchers from Freiburg and Bonn have succeeded in developing the basics for new therapies in particular for the treatment of advanced prostate cancer.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-improving-the-success-of-treatment
  • Article - 18/08/2016 Schematic showing the excretion of toxic proteins. Specifically, the schematic shows a bacterial cell and a human cell (circles) and toxic products (small dots) that dock to cells.

    Moonlighting proteins can make bacteria pathogenic

    The mechanism underlying the export of biomolecules from cells remains unknown. Prof. Dr. Friedrich Götz and his team at the Institute of Microbial Genetics at the University of Tübingen have found out that staphylococci can turn into dangerous pathogens by excreting normally harmless enzymes. The researchers believe that the enigmatic excretion of such enzymes is due to a completely new mechanism and are thus planning to carry out further…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/moonlighting-proteins-can-make-bacteria-pathogenic
  • Article - 03/10/2010 12438_de.jpg

    ColepCCL: A creative hub to prepare for the company’s move into the life sciences

    ColepCCL Rapid-Spray a ColepCLL subsidiary based in Laupheim Germany has made a name for itself as the largest European contract filler of aerosols. However ColepCLL which employs around 3500 people in five countries is now planning to open up new fields of activity in the life sciences area.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/colepccl-a-creative-hub-to-prepare-for-the-company-s-move-into-the-life-sciences
  • Dossier - 02/06/2014 13521_de.jpg

    Bioanalysis – techniques for the characterization of biological material

    Science constantly provides researchers with new challenges biologists and bioanalysts have to deal with and which come from sources as varied as the ever increasing number of resistant pathogenic bacterial strains or the famine conditions in Third-World countries. In the search for scientific truths bioanalysis is the development optimization and application of the entire range of analytical methods available. However we need to keep in mind…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/bioanalysis-techniques-for-the-characterization-of-biological-material
  • Article - 30/01/2012 16256_de.jpg

    Silicone application in medical technology

    Silicone is flexible, biocompatible and heat-resistant, characteristics that make organosilicone compounds ideal for a wide range of applications in medical technology. Up until now, the broad application of such compounds has been hampered chiefly by the high surface friction of silicone. The Reutlingen-based company Silcos GmbH has developed special methods for the treatment of surfaces that considerably improve the compound's range of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/silicone-application-in-medical-technology
  • Article - 22/12/2014 22598_de.jpg

    Fighting hepatitis viruses with their own weapons

    Virologist Prof. Dr. Stephan Urban from the University of Heidelberg has been awarded the DZIF Prize for Translational Infection Research for the discovery and development of a promising peptide drug for the treatment of hepatitis B virus infections. The peptide prevents viruses from entering the liver cells, and is also effective against hepatitis D infection. Hepatitis D is the deadliest of all viral liver diseases and no specific antiviral…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/fighting-hepatitis-viruses-with-their-own-weapons
  • Dossier - 22/02/2010 10749_de.jpg

    Respiratory disease - congestion in the respiratory system

    Lung diseases are by far the most frequent cause of death worldwide. Every year three million people die from chronic obstructive pulmonary diseases 2.3 million die from lung cancer and 1.5 die from tuberculosis WHO World Health Organisation. There is no improvement in sight and experts believe that the number of deaths will continue to rise particularly in the case of chronic obstructive pulmonary diseases COPD lung cancer and tuberculosis TB.…

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/respiratory-disease-congestion-in-the-respiratory-system
  • Press release - 10/07/2008

    New pharmacological study for leukaemia patients

    Julia Kirchheiner from Ulm is examining why some leukaemia patients do not respond to cytarabin treatment. She is now hoping to identify the genetic factors that come together to determine how a patient responds to cytarabin treatment.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-pharmacological-study-for-leukaemia-patients
  • Article - 18/01/2018 Teaser-Mutationen-Primartumor.png

    Medications that target metastasing tumours

    Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
  • Article - 10/06/2014 21505_de.jpg

    Ribosome assembly as target for innovative antibiotics

    Although bacterial ribosomes are a popular target of common antibiotics, there are no drugs that specifically target ribosome assembly. To date, there is simply no screening method that would be suitable for assaying inhibitors of ribosomal subunit assembly. Prof. Dr. Elke Deuerling and Dr. Rainer Nikolay from the University of Konstanz have now achieved a breakthrough. They have developed a method that enables the high-throughput identification…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/ribosome-assembly-as-target-for-innovative-antibiotics
  • Press release - 30/03/2009

    Stem Cells: Deathly Awakening by Interferon

    Interferon-alpha, a messenger substance of the immune system, awakens dormant hematopoietic stem cells in the bone marrow to become active, thus making them vulnerable for the effect of many drugs. This finding was published in Nature by researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) jointly with colleagues from Lausanne. The researchers suppose that this might also be a way to stimulate tumor stem…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deathly-awakening-by-interferon
  • Article - 19/07/2016 Symbolic 3D model with a T cell equipped with CAR and the relevant DNA.

    Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
  • Article - 04/07/2011 14640_de.jpg

    The adhesion of cells to the endothelium and to artificial surfaces

    Professor Stefan W. Schneider from the Mannheim Medical Faculty is investigating the function of the vascular endothelium and its interaction with blood and tumour cells using microfluidics methods that enable him to measure the adhesion of cells to the walls of blood vessels under physiological flow conditions. As part of an interdisciplinary project, he is investigating the characteristics of wafer-thin surfaces covered with living cells, which…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-adhesion-of-cells-to-the-endothelium-and-to-artificial-surfaces
  • Press release - 14/01/2009 07820_de.jpg

    Hunters of lost treasures

    On 1st December 2008 Prof. Dr. Karl Schmid the first person to hold the F.W. Schnell Foundations endowed professorship for crop biodiversity and breeding informatics started the ball rolling on a unique European-wide project. Schmid and his colleagues are searching gigantic databases in which genetic analyses and plant descriptions are stored for hidden treasures.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/hunters-of-lost-treasures
  • Press release - 22/06/2009 08887_de.jpg

    Many animal experiments are superfluous

    Researchers at the Esslingen University of Applied Sciences are working on an alternative to the large number of animal experiments that are still being carried out. Researchers under the leadership of Prof. Dr. Bettina Weiß have received a grant from the Landesstiftung Baden-Württemberg foundation for work on this particular research area.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/many-animal-experiments-are-superfluous
  • Press release - 31/01/2012 10938_de.jpg

    HITS Scientist Rebecca Wade receives professorship at the University of Heidelberg

    Today, Dr. Rebecca Wade, head of the “Molecular and Cellular Modelling” research group at the Heidelberg Institute for Theoretical Studies (HITS), has been appointed to the W3 professorship “Computational Structural Biology” (Faculty of Biosciences/HITS) at the University of Heidelberg.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/hits-scientist-rebecca-wade-receives-professorship-at-the-university-of-heidelberg
  • Press release - 04/11/2016

    Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-therapeutics-announces-upcoming-us-patent-issuance-for-mek-treatment-against-viral-diseases
  • Article - 18/05/2013 19744_de.jpg

    Biofilm research aims at fighting hospital germs

    Pseudomonas aeruginosa is a common bacterium that can be found in many different places – soil, water, washing basins, toilets and washing machines, to name but a few examples. Due to its resistance to antibiotic treatment, P. aeruginosa is mainly known as the cause of hospital-acquired infections. David Schleheck, a biologist from Konstanz University, deals specifically with the bacterium’s presence in biofilms. His research could open up new…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/biofilm-research-aims-at-fighting-hospital-germs

Page 4 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • sb_theme_biopro.domain.mdr-ivdr
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search